Chlorobutanol

Evidence Level: L5

Predicted Indications: 9

Chlorobutanol

Pharmacist Assessment Report

Chlorobutanol: From Ear Wax Softening (Cerumol) to Erectile Dysfunction (disease)

One-Sentence Summary

Chlorobutanol is a preservative with mild sedative and local anaesthetic properties. It is marketed in Australia as an ingredient of Cerumol ear drops, and the data compiled for this report do not state an approved indication. The TxGNN model predicts it may be effective for erectile dysfunction, but no clinical trials and no publications currently support this prediction.

Quick Overview

Item	Content
Original Indication	Not stated in the data compiled for this report (the product is an ear-drop formulation)
Predicted New Indication	Erectile dysfunction
TxGNN Prediction Score	0.9979
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Chlorobutanol is a chloroform-derived preservative with mild sedative and local anaesthetic properties. In Australia it is present in a multi-ingredient ear-drop product, and no approved indication text was captured for that product.

No mechanistic link to erectile dysfunction has been established. The high TxGNN score (0.9979) is a computational prediction only and should not be read as evidence of efficacy.

Other top-ranked predictions include migraine disorder (0.9971), migraine with brainstem aura (0.9958), Tourette syndrome (0.9954), trichotillomania (0.9950) and attention deficit-hyperactivity disorder (0.9941). The migraine-related scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, so they are likely not independent findings. Most of the remaining predictions are rare conditions with no plausible mechanistic rationale. None has supporting trials or literature.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 4180B	Cerumol	Ear drops: ortho-dichlorobenzene 140 mg/mL, para-dichlorobenzene 20 mg/mL, chlorobutanol hemihydrate 50 mg/mL, arachis oil 573 mg/mL, 10 mL	Not stated in the data compiled

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Note that Cerumol contains arachis (peanut) oil, which is relevant to patients with peanut allergy. This is a general formulation observation drawn from the listed ingredients, not from the compiled safety data. No drug interaction records were found.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone (Evidence Level L5). There are no clinical trials, no publications and no known mechanistic link between chlorobutanol and erectile dysfunction. The only Australian product is a topical ear preparation, so route compatibility with any systemic indication is also unresolved.

To proceed, the following is needed:

Mechanism of action data for chlorobutanol
Approved indication text and Product Information (warnings and contraindications) for Cerumol
A literature and trial search to find any supporting evidence for erectile dysfunction, or for the migraine predictions if these are prioritised
Assessment of route and formulation compatibility, since the only marketed product is an ear drop
Review of whether the predicted indications are clinically meaningful treatment targets (for example, a genetic susceptibility phenotype is not one)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.